Our Purpose
The Clinical Proteomics Platform aims to exploit the latest technological developments in mass spectrometry and immunoassay for the discovery, validation and use of biomarkers in various human pathologies (proteins, RNA, DNA, metabolites).
Our Approach
Several technological approaches oriented towards the use of clinical samples and high throughput are available, including mass spectrometry (MRM and HRMS) and ultra-sensitive immunoassays (SIMOA and MSD).
Our Mission
Integrated in the Montpellier Proteome Cluster since its creation and IBiSA labeled, its mission is equally to make medical, biological and technical expertise in Clinical Proteomics available to academic and industrial teams. The PPC has been ISO 9001 certified since 2014.
Last news :
Poster AAIC
For the Alzheimer’s Association International Conference (AAIC), our assistant engineer Jana Kindermans made a scientific poster on the early detection of Alzheimer’s disease biomarker, namely plasma amyloid peptides. For the quantification of these plasma amyloid...
lire plus
Marie-Laure PONS gave a presentation
Recently, our PhD student Marie-Laure PONS gave a presentation for her the thesis follow up committee. After one year of doing research and experimenting, her topic is beginning to take shape: the development of an innovative multiplex and targeted mass spectrometry...
lire plus
CoVIMOD
Very proud of the financial support of @IsiteMUSE for our new CoVIMOD project dealing with an exhaustive analysis of the modification landscape of viral and cellular RNAs in SARS-CoV2 infection and the study of their functional impact on virus replication and cell...
lire plus
The PPC in a nutshell :
Employees
Years of experience
Ongoing projects
Patents
Clinical Proteomics Platform
Institute for Regenerative Medicine & Biotherapy (IRMB)
Hôpital Saint Eloi
80 rue Augustin Fliche
34295 MONTPELLIER – Cedex 5
FRANCE